BACKGROUND: Many alterations in extracellular metabolism of @entity460 have been associated to @entity101 , but the number of studies relating this disease with @entity170 is extremely low. This study clarifies the therapeutic effect of three treatments- @entity9383 , @entity9383 + @entity918 ( @entity918 ), @entity4688 -on bone remodeling markers, @entity79 ( @entity79 ) in @entity101 @entity1 , and relationship with @entity1289 ( @entity1289 ) polymorphism. METHODS: This open, prospective study included 134 @entity1 with low-to-moderate @entity101 and stable @entity79 according to Joint National Committee criteria and 96 @entity1 completed the study. After a washout period, @entity1 were randomized to one of the three treatments, which they received for 1 year. Analyses of blood and urine samples and densitometric studies on lumbar spine were performed. RESULTS: @entity460 and @entity14257 levels increased (9.5 +/-0.3 and 9.6 +/-0.3 mg/dL, P =.01 and 46 +/-22 and 58 +/-22 nmol/L, P =.026, respectively) in the @entity9383 -treated group and @entity460 levels increased (9.4 +/-0.6 and 9.8 +/-0.4 mg/dL, P =.001) in the @entity9383 - @entity918 -treated group. The @entity10692 levels, calciuria, and @entity460 / @entity1011 ratio decreased (64 +/-23 and 43 +/-16 nmol/L, P =.0001;209 +/-93 and 161 +/-93 mg/24 h, P =.0022;0.21 +/-0.09 and 0.17 +/-0.11, P =.04, respectively). In the @entity4688 -treated group @entity10692 levels (61 +/-27 and 42 +/-19 nmol/L, P =.0022) decreased. Only @entity1 presented a statistical significance (1.064 +/-0.16 g/cm(2), P =.034) between ID+II polymorphism and @entity79 decrease, and between DD polymorphism with less @entity79 under baseline conditions and a @entity79 increase (1.070 +/-0.16 g/cm(2), P =.017) after @entity1289 inhibitor treatment. CONCLUSIONS: The @entity1289 inhibitors have a beneficial effect on @entity79 and @entity460 metabolism alterations in @entity101 subjects. Concerning @entity79 response, @entity1 presenting with the II+ID polymorphism had a poor response to antihypertensive drug treatment, whereas @entity1 with the DD polymorphism responded better. This is the first study demonstrating a relationship between @entity1289 polymorphism and @entity79 response and antihypertensive @entity1289 inhibitor treatment.

Effect of @entity9383 , @entity9383 - @entity918 , and @entity4688 on the bone mass of XXXX subjects: relationship with @entity1289 polymorphisms.

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity4688 :: ('MESH:D004656', 'Chemical') :: ['enalapril'] @entity1289 :: ('1636', 'Gene') :: ['angiotensin converting enzyme', 'ACE'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'hypertensive'] @entity9383 :: ('MESH:C041125', 'Chemical') :: ['quinapril'] @entity918 :: ('MESH:D006852', 'Chemical') :: ['HCTZ', 'hydrochlorothiazide'] @entity10692 :: ('MESH:C097949', 'Chemical') :: ['1, 25-dihydroxyvitamin D'] @entity170 :: ('MESH:D010024', 'Disease') :: ['osteoporosis'] @entity79 :: ('MESH:D001847', 'Disease') :: ['bone mineral density', 'BMD'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium', 'Calcium'] @entity14257 :: ('MESH:C104450', 'Chemical') :: ['25-hydroxyvitamin D'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']
@entity101 :: (MESH:D006973,Disease) :: ['hypertensive']
